XOMA Ltd. is a biopharmaceutical company that develops and manufactures products to treat immunologic and inflammatory disorders, cancer and infectious diseases. The Company's products are in various stages of development, and most are subject to regulatory approval before XOMA or its collaborators can commercially introduce any products. The Company has one United States Food and Drug Administration (FDA) approved product, RAPTIVA, which has been commercially introduced under a collaboration agreement with Genentech, Inc.